Compare
ResMed Inc vs Dexcom Inc vs West Pharmaceutical Services Inc vs Globus Medical Inc
| Latest fiscal year | ResMed Inc RMD | Dexcom Inc DXCM | West Pharmaceutical Services Inc WST | Globus Medical Inc GMED |
|---|---|---|---|---|
| Year ended | 2026-06-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $5.65B | $4.66B | $3.07B | $2.94B |
| Revenue growth (YoY) | +9.9% | +15.6% | +6.3% | +16.7% |
| Gross margin | 61.1% | 60.1% | 35.9% | 67.4% (computed) |
| Operating margin | 33.4% | 19.6% | 19.0% | 16.3% |
| Net margin | 26.9% | 17.9% | 16.1% | 18.3% |
| Net income | $1.52B | $836.30M | $493.70M | $537.87M |
| EPS (Diluted) | $10.43 | $2.09 | $6.79 | $3.92 |
| Operating cash flow | $1.81B | $1.44B | $754.80M | $753.45M |
| Free cash flow | $1.65B | $1.08B | $468.90M | $588.77M |
| Cash & equivalents | $1.47B | $917.70M | $791.30M | $526.16M |
| Total assets | $8.97B | $6.34B | $4.27B | $5.30B |
| Total liabilities | $2.38B | $3.59B | $1.09B | $729.51M |
| Shareholders' equity | $6.59B | $2.75B | $3.18B | $4.57B |
| Return on year-end equity | 23.1% | 30.5% | 15.5% | 11.8% |
| Shares outstanding | 144.24M | 384.80M | 72.00M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | ResMed Inc | Dexcom Inc | West Pharmaceutical Services Inc | Globus Medical Inc |
|---|---|---|---|---|
| Latest | $5.65B Ended 2026-06-30 | $4.66B Ended 2025-12-31 | $3.07B Ended 2025-12-31 | $2.94B Ended 2025-12-31 |
| 1 year earlier | $5.15B Ended 2025-06-30 | $4.03B Ended 2024-12-31 | $2.89B Ended 2024-12-31 | $2.52B Ended 2024-12-31 |
| 2 years earlier | $4.69B Ended 2024-06-30 | $3.62B Ended 2023-12-31 | $2.95B Ended 2023-12-31 | $1.57B Ended 2023-12-31 |
| 3 years earlier | $4.22B Ended 2023-06-30 | $2.91B Ended 2022-12-31 | $2.89B Ended 2022-12-31 | $1.02B Ended 2022-12-31 |
| 4 years earlier | $3.58B Ended 2022-06-30 | $2.45B Ended 2021-12-31 | $2.83B Ended 2021-12-31 | $958.10M Ended 2021-12-31 |